The Challenges of Accelerated Approval for Cancer Treatment

The accelerated approval pathway allows products to come to market with more uncertainty. The trials are smaller and they're focused on endpoints that are not definitive in terms of whether patients will benefit from the products. This trade off of uncertainty was always considered acceptable in the context of oncology, which is why it's been used so frequently. We've seen signs that the agency wants to use this pathway more aggressively.